COMPANY

Response Pharmaceuticals

HQ: Falls Church, VA source · responsepharmaceuticals.com ↗

Location: Falls Church, VA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Triglycerides Weight Gain Trajectory Elevated Cholesterol Raynaud's Disease Drug-induced Weight Gain Hypertriglyceridemia Type 2 Diabetes Type 2 Diabetes Mellitus Hyperlipidemia RDX-002 SLx-2101 SLx-4090 KD026

7Trials (company is sponsor)

Timeline

Sep 27, 2024 Trial start Phase 2: Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists source ↗
May 16, 2023 Trial start Phase 1: Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine source ↗
2015-04 Trial start Phase 2: Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus source ↗
2009-04 Trial start Phase 2: A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes source ↗
2009-01 Trial start Phase 2: Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia source ↗
2007-06 Trial start Phase 2: Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease source ↗
2007-05 Trial start Phase 2: Evaluation of Safety and Effects of SLx-4090 After Dosing for 14 Days in Subjects With High Triglycerides source ↗

Clinical trials (lead sponsor) 7

Record	Title	Phase	Status	Start	Primary completion
NCT06640972	Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists	Phase 2	Completed	Sep 27, 2024	Jan 4, 2025 (actual)
NCT00528242	Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease	Phase 2	Completed	2007-06	2008-03 (actual)
NCT05857566	Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine	Phase 1	Completed	May 16, 2023	Jul 13, 2023 (actual)
NCT00562575	Evaluation of Safety and Effects of SLx-4090 After Dosing for 14 Days in Subjects With High Triglycerides	Phase 2	Completed	2007-05	2008-02 (actual)
NCT00871936	A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes	Phase 2	Completed	2009-04	2009-10 (actual)
NCT02434744	Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus	Phase 2	Completed	2015-04	2016-03 (actual)
NCT00810979	Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia	Phase 2	Completed	2009-01	2009-09 (actual)